Lifestance Health Group, Inc. - LFST STOCK NEWS

LifeStance Health released a survey revealing concerning trends in social media's impact on mental health self-diagnosis. The study found that 29% of Americans self-diagnose mental health conditions based on social media content, with only 47% of these individuals consistently seeking professional guidance.

The survey highlighted that 54% of respondents encounter mental health misinformation weekly on social media, while 23% seek mental health advice on these platforms. Among generations, Gen Z (50%) and millennials (38%) lead in self-diagnosis rates.

Key findings show 26% of respondents check social media within five minutes of waking up, and 76% find the idea of a digital detox appealing. The study also revealed that 40% of respondents frequently encounter clinical terms like "trauma" and "narcissist" on social media, with 32% reporting that such content has led them to question their relationships.

LifeStance Health Group (Nasdaq: LFST) announced significant leadership changes, with Dave Bourdon appointed as the new CEO effective March 3, succeeding Ken Burdick who will transition to Executive Chairman. Bourdon, who joined as CFO in 2022, brings over two decades of healthcare and mental health industry experience.

Ryan McGroarty, with 25 years of healthcare experience including 15 years in CFO roles, will become the new Chief Financial Officer effective March 17. Under Burdick's leadership since September 2022, LifeStance has met or exceeded expectations for nine consecutive quarters.

Bourdon previously served as CFO of Magellan Health and held positions at Cigna, while McGroarty comes from Help at Home where he served as CFO and previously held multiple CFO roles at Cigna.

LifeStance Health Group (NASDAQ: LFST) reported strong financial results for Q4 and full year 2024. Full-year revenue grew 19% to $1.251 billion, while Q4 revenue increased 16% to $325.5 million.

Key highlights include:

• Clinician base grew 12% to 7,424, adding 779 clinicians in 2024
• Visit volumes rose 15% to 7.9 million for the full year
• Generated $107.3 million in operating cash flow
• Adjusted EBITDA doubled to $119.7 million
• Free Cash Flow reached $85.7 million

For 2025, LifeStance projects revenue between $1.40-1.44 billion and Adjusted EBITDA of $130-150 million. Q1 2025 guidance expects revenue of $320-340 million.

LifeStance Health Group (NASDAQ: LFST), a major provider of outpatient mental health care services, has announced it will release its fourth quarter and full year 2024 earnings report before market opening on Thursday, February 27, 2025.

The company will host a live earnings conference call at 8:30 a.m. Eastern Time on the same day. Investors can participate by dialing 1-800-715-9871 (domestic) or 1-646-307-1963 (international) using conference ID 4372752. A live audio webcast will be available through the Events and Presentations section of LifeStance's Investor Relations website, where related materials will be posted before the call. A replay will be accessible afterward on the same platform.

LifeStance Health Group reported strong Q3 2024 results with revenue increasing 19% to $312.7 million. The company's clinician base grew 13% to 7,269, with visit volumes up 15% to 2.0 million. Net loss improved significantly to $6.0 million from $61.6 million in Q3 2023. Adjusted EBITDA more than doubled to $30.7 million. The company raised its full-year 2024 guidance, now expecting revenue between $1.228-1.248 billion and Adjusted EBITDA of $105-115 million. Cash flow from operations reached $44.9 million for the first nine months of 2024.

LifeStance Health Group, Inc. (NASDAQ: LFST), a major provider of outpatient mental health care in the United States, has announced its plans to release third quarter 2024 earnings before the market opens on Thursday, November 7, 2024. The company will host a live earnings conference call on the same day at 8:30 a.m. Eastern Time to discuss the results.

Interested parties can participate in the call by dialing 1-800-715-9871 (domestic) or 1-646-307-1963 (international) and using the conference ID 2787723. A real-time audio webcast will be available on the LifeStance Investor Relations website, where related materials will be posted prior to the call. A replay of the webcast will be accessible after the conference call concludes.

A LifeStance Health survey reveals widespread election-related anxiety among Americans, with 79% experiencing anxiety over the 2024 U.S. presidential election. Key findings include:

• Younger generations are more likely to experience moderate to significant election-related anxiety
• 57% think about the election daily
• 60% of respondents in therapy discuss politics during sessions
• 44% report conflicts in personal relationships due to political discussions
• 33% would not date someone with opposing political views
• 72% say social media and news coverage contribute to election anxiety

The survey underscores the need for accessible mental healthcare to help people navigate election-related stress and maintain overall well-being. Dr. Ujjwal Ramtekkar, Chief Medical Officer at LifeStance, emphasizes the importance of mental health care in managing daily life stressors and building long-term resilience.

LifeStance Health Group (NASDAQ: LFST), a leading outpatient mental health care provider, has announced its participation in the 22nd Annual Morgan Stanley Global Healthcare Conference in New York City. The company's CFO, Dave Bourdon, will present on Wednesday, September 4, 2023, at 10:00 a.m. Eastern time. The presentation will be moderated by Craig Hettenbach.

Investors and interested parties can access the live webcast of the presentation through the Events and Presentations section of LifeStance Health's Investor Relations website. A replay of the webcast will also be available after the event concludes. This conference provides LifeStance an opportunity to showcase its position in the mental health care sector and update investors on its business strategies and performance.

LifeStance Health Group (Nasdaq: LFST) reported strong Q2 2024 results, with revenue increasing 20% to $312.3 million. The company's clinician base grew 14% to 6,984, and visit volumes rose 15% to 2.0 million. Despite a net loss of $23.3 million, Adjusted EBITDA improved significantly to $28.6 million, up 103% year-over-year.

LifeStance raised its full-year 2024 guidance, now expecting revenue between $1.2 billion to $1.242 billion, Center Margin of $363 million to $383 million, and Adjusted EBITDA of $90 million to $100 million. The company also reiterated expectations for positive Free Cash Flow for the year.